Psychedelics for Neurodegeneration: Huntington's, Dementia, and the Evidence Gap

The mechanistic case for psychedelics in neurodegenerative disease is genuinely interesting. The human clinical evidence is close to non-existent, and the gap between those two statements is the entire story. ## The argument Neurodegenerative diseases involve progressive loss of neurons and synapses. Psilocybin promotes synaptic growth and increases synaptic density in preclinical models, via BDNF and mTOR signalling — see Psilocybin's Neuroplasticity Mechanism: 5-HT2A, Glutamate, BDNF and mTOR. If plasticity can be pharmacologically increased, perhaps it partly offsets ongoing loss. It is a clean, appealing single-lever story, which is a reason for caution rather than confidence. ## Huntington's disease: a protocol, not a trial **There is no clinical trial of psilocybin in Huntington's disease.** The concrete artifacts are a *proposed research protocol* published in an undergraduate research-protocol journal, plus review-level argument that the neuroprotective and neurotrophic properties of 5-HT2A agonists could in principle slow neuronal loss. Huntington's is a plausible "why not try" target precisely because nothing currently slows or stops its progression, which raises the tolerance for speculative approaches. That is a statement about the unmet need, not about the evidence. **A search hazard worth recording:** articles titled along the lines of "a new hope for patients with Huntington's disease" are frequently about **AMT-130**, an AAV gene therapy delivering a microRNA to silence mutant HTT — a completely different intervention. Searching for psychedelic-related Huntington's news reliably surfaces gene-therapy results, and conflating them produces a badly wrong impression of the state of the field. ## Dementia: one case report and one indirect trial The dementia coverage that circulates traces largely to a **2026 case report** (published in *Frontiers in Neuroscience*): an octogenarian woman with ten years of Alzheimer's disease and five years of severe decline — near-monosyllabic speech, fully dependent — given psilocybin-containing mushrooms under supervision, with a second smaller dose a month later. Observed afterwards: independent walking and self-dressing within days, restoration of continence after more than five years, spontaneous autobiographical speech about 19 hours post-dose, and increased facial expressivity and social reciprocity, with continence maintained at one-month follow-up. The authors themselves stress the limits, and they are severe: **n = 1**, no neuroimaging, no standardised cognitive scales, no way to exclude spontaneous fluctuation, and improvements explicitly characterised as transient rather than as disease reversal. Separately, a **pilot trial running to December 2026** gives psilocybin to people with mild cognitive impairment or early Alzheimer's — but it targets **depression** in that population, not the dementia pathology. Results are not yet available. Review articles make the mechanistic case while conceding that human clinical data in dementia are lacking. ## The honest position A vivid single case is being circulated as though it were a trial. It is not. The state of evidence is: mechanistic plausibility, animal and cell data, one uncontrolled case report, and proposed protocols. What would actually move this: the December 2026 pilot readout, any *registered* Huntington's trial rather than a protocol, and independent replication of the preclinical findings. See The Clean Single-Lever Pattern: Why Simple Biological Mechanisms Disappoint in Trials and Psilocybin Misconceptions: Case Reports, Blinding, and Headline Inflation.